Peptide drugs are experiencing renewed growth as improved design and delivery technologies help address historical barriers, such as instability, rapid clearance, poor permeability, and limited oral bioavailability.
GLP-1 therapies have become the most visible example of modern peptide drug success, demonstrating how structural modification and half-life extension can support practical dosing for large chronic-disease populations.
Peptides occupy an important middle ground between small molecules and biologics, offering high target specificity and synthetic flexibility while requiring careful optimization for stability, exposure, delivery, and manufacturability.
AI and machine-learning tools may accelerate peptide drug discovery by helping researchers explore sequence space, structure–activity relationships, and developability risks, but experimental validation remains essential.
The next phase of peptide therapeutics will depend not only on better molecular design but also on scalable synthesis, purification, quality control, and supply chain strategies that can support growing clinical and commercial demand.
Introduction: Why Peptides Are Back
Peptide therapeutics are not new, but they are entering a new phase of relevance. Long valued for their ability to engage biological targets with high specificity, peptides have also carried persistent development liabilities, including limited stability, rapid clearance, and delivery challenges. Advances in peptide design and synthesis, display technologies, delivery systems, bioengineering, and artificial intelligence (AI) are now making it more feasible to address those limitations earlier in development).
That progress is expanding the role of peptides across a wide range of applications. Peptide-based drugs and peptide-enabled platforms are relevant not only in diabetes and weight management but also in oncology, rare diseases, diagnostics, targeted delivery systems, and vaccines.1 Glucagon-like peptide-1 (GLP-1) drugs have brought extraordinary attention to the field, but they are part of a larger movement toward therapeutic modalities that can be designed with greater molecular precision.
The foundation for that resurgence was visible before the current GLP-1 boom. By 2020, more than 100 peptide drugs had been approved for therapeutic or diagnostic applications, reflecting decades of accumulated clinical, regulatory, and manufacturing experience. What has changed is the level of sophistication now being applied to peptide candidates. Developers are increasingly using structural modification, formulation strategies, and platform technologies to build better developability into peptide drugs from the beginning.
2
Peptides now sit at the intersection of biological specificity, synthetic flexibility, and precision-targeted drug development. Their renaissance is therefore not merely a return to an established class of medicines. It reflects a broader shift in how the industry approaches molecular design: identifying the liabilities of a promising therapeutic format early and engineering around them through coordinated advances in chemistry, delivery, analytics, and manufacturing.
Why Peptides Fit the Precision Medicine Era
The renewed interest in peptide drugs reflects a broader shift toward molecules that can engage biological systems with greater precision. Peptides are often described as occupying a middle ground between small molecules and biologics, combining features that are difficult to capture in either category alone. They can offer high target specificity and comparatively lower immunogenicity while still being produced through synthetic approaches that can support cost-effective manufacturing relative to more complex biologic systems.3
That intermediate position is important. Small molecules remain powerful because they can often be delivered orally, manufactured efficiently, and distributed broadly, but they may struggle to modulate certain protein–protein interactions or highly selective biological pathways. Biologics can achieve exquisite specificity, but their size, complexity, immunogenicity considerations, and manufacturing demands create a different set of development and access challenges. Peptides can sometimes bridge those worlds, offering enough structural complexity to interact selectively with biological targets while remaining more synthetically tractable than many larger biologics.
This makes peptides especially relevant in the precision medicine era, where the goal is not simply to affect a broad pathway but to engage the right target, in the right tissue, for the right patient population. Their amino acid–based structures can be modified to tune potency, selectivity, receptor bias, half-life, and other drug-like properties. That flexibility allows developers to think of peptide candidates not as fixed natural sequences but as designable therapeutic scaffolds.
At the same time, peptide therapeutics continue to face obstacles related to metabolic stability, oral bioavailability, and permeability.4 Their promise depends on deliberate optimization: specificity must be matched by sufficient stability, exposure, delivery feasibility, and manufacturability.
GLP-1s as the Public Face of the Peptide Renaissance
GLP-1 receptor–based medicines have made the peptide resurgence visible to clinicians, patients, investors, and manufacturers. Their success has shifted perceptions of peptides from a specialized modality with known limitations to a major platform for chronic disease intervention.
Zepbound offers a clear example. The FDA approved Zepbound for chronic weight management in November 2023, for adults with obesity or adults with overweight who have at least one weight-related condition.5 Its active ingredient, tirzepatide, activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors and is administered once weekly by subcutaneous injection. That dosing profile reflects a key theme in the broader peptide resurgence: successful peptide drugs must do more than bind the right target. They must also sustain exposure, fit into patient routines, and deliver a practical therapeutic profile.
Tirzepatide illustrates how structural design can help address those requirements. It is a 39-amino-acid modified peptide based on the GIP sequence and includes a C20 fatty diacid moiety that enables albumin binding and prolongs half-life.6 The molecule is not simply a naturally occurring signaling peptide repurposed as a drug; it is a deliberately modified therapeutic designed to extend exposure and support once-weekly dosing.
Semaglutide provides another prominent example of peptide-based metabolic therapy. Wegovy is a GLP-1 receptor agonist indicated, alongside a reduced-calorie diet and increased physical activity, for chronic weight management in adults who meet defined body mass index criteria.7 Products like Wegovy and Zepbound have made peptide drugs central to one of the most commercially and clinically visible areas of modern medicine.
The significance of GLP-1s extends beyond obesity and diabetes. They show how peptide drugs can be engineered to improve pharmacokinetic behavior, support practical dosing, and address large patient populations. That success has made the peptide modality more visible, but it should be understood as a proof point rather than the whole story.
Beyond GLP-1s: A Broader Therapeutic and Diagnostic Expansion
The visibility of GLP-1 drugs can make the peptide resurgence appear narrower than it is. Metabolic disease has become the most public proof point, but peptide innovation now extends across a much broader therapeutic and diagnostic landscape. Peptides are being explored and used across therapeutic, diagnostic, vaccine, and targeted-delivery applications, reflecting their versatility as both active drugs and functional components of more complex platforms.1
That breadth places peptides within the larger rise of targeted modalities. The same features that make peptides attractive as drugs, including specificity, tunable structure, and biological recognition, also make them useful beyond traditional receptor agonism or antagonism. Peptides can function as targeting ligands, diagnostic agents, delivery-enabling motifs, vaccine components, or payload elements within conjugated systems. Their resurgence is therefore not limited to the growth of standalone peptide therapeutics; it also reflects their increasing utility as modular tools for directing, stabilizing, or enhancing other therapeutic strategies.
The recent regulatory landscape reinforces that peptides are advancing alongside other precision-oriented medicines. In 2024, the U.S. Food and Drug Administration (FDA) approved 50 novel drugs, including four TIDES: two peptides and two oligonucleotides.3 In 2025, the FDA approved 46 novel drugs, including one peptide, three oligonucleotides, and one antibody–drug conjugate (ADC) containing a peptide payload.8 While annual approval numbers fluctuate, these examples show that peptides are part of a broader shift toward modalities whose structures and functions can be tailored to specific targets, tissues, mechanisms, and delivery needs.
Engineering Around Peptides’ Historical Liabilities
The peptide resurgence has been enabled by a change in how developers approach the liabilities that have long constrained the modality. Peptides can be highly selective and biologically potent, but many are also vulnerable to rapid clearance and degradation, and subcutaneous injection is often required to achieve useful exposure.1 Those challenges have not disappeared. What has changed is the extent to which they can be addressed through deliberate molecular design.
In earlier development paradigms, a promising peptide sequence might be evaluated largely for biological activity first, with stability and half-life addressed later. Modern peptide development increasingly takes a more integrated view. Affinity remains important, but developers must also consider whether the molecule can resist enzymatic degradation, maintain sufficient circulation time, reach the intended site of action, and support an acceptable dosing interval.
Several design strategies illustrate this shift. Cyclization, lipidation, and PEGylation are among the approaches being explored to improve peptide stability and pharmacokinetic behavior.3 These modifications can reshape how a peptide behaves in the body, including how long it persists and how often it may need to be administered. The success of long-acting metabolic peptides has made this principle especially visible, but the same logic applies across the field: the therapeutic value of a peptide depends on whether its exposure profile can be made clinically practical.
Non-natural amino acids add another layer to the design toolkit. By expanding beyond standard amino acid building blocks, developers can modify peptide structure in ways that enhance binding affinity, metabolic stability, and in vivo half-life.4 This creates opportunities to tune peptide candidates with greater precision, but it also introduces new development considerations. Each modification can influence synthesis, purification, impurity control, analytical characterization, and ultimately manufacturability.
The most successful peptide programs are therefore likely to treat stability, exposure, and developability as connected design criteria. A modification that improves half-life may still need to be evaluated against synthesis, purification, and product-quality requirements. For modern peptide development, the central question is not only whether a sequence is active, but whether it can become a practical therapeutic product.
Delivery Remains the Central Challenge
Even as peptide design becomes more sophisticated, delivery remains one of the central constraints shaping the field. Many of the same properties that make peptides biologically useful also make them difficult to administer in convenient ways. They can be vulnerable to degradation, may have limited permeability, and often require formulation or route-of-administration strategies that differ from those used for conventional small molecules. The peptide renaissance therefore depends on delivery as much as design.
Current development patterns show how persistent this challenge remains. Among peptide-based drugs approved from 2014 through 2024, subcutaneous injection was the most prevalent route of administration, and subcutaneous dosing also dominated phase III clinical trials during that period.1 That trend reflects both progress and limitation. Subcutaneous delivery can support effective chronic therapy, including less frequent dosing for long-acting peptides, but it still creates practical considerations around injection burden, device design, patient training, tolerability, adherence, and large-scale supply of finished drug-device presentations.
Oral delivery remains especially difficult. Peptide therapeutics continue to face challenges related to oral bioavailability and permeability, which limits how easily they can be absorbed and maintain sufficient exposure after administration.4 The gastrointestinal environment presents multiple barriers, including degradation before absorption and limited transport across epithelial tissues. For many programs, those barriers mean that a biologically compelling peptide may still require injectable delivery unless the molecule, formulation, or delivery system can be engineered to overcome them.
This delivery challenge will continue to influence which peptide drugs advance, how they are positioned clinically, and what kinds of product profiles are commercially viable. A peptide intended for a rare or severe disease may be acceptable as an injectable therapy if the clinical benefit is significant. A peptide intended for a large chronic population may face a higher bar for dosing convenience, device usability, and supply reliability. In both cases, delivery strategy must be considered early, because route of administration affects patient experience, formulation development, stability requirements, manufacturing processes, packaging, and life cycle planning.
AI, Databases, and Design Automation
AI is becoming part of the peptide discovery conversation because the modality presents a vast and highly tunable design space. Peptide sequence, length, conformation, charge, hydrophobicity, stability, and modification pattern can all influence therapeutic behavior, creating more possible candidates than traditional empirical screening can easily explore. AI and machine-learning methods are being investigated as tools for peptide-based drug discovery and more accurate peptide analysis, including through predictive databases and computational approaches that can help evaluate potential peptide candidates.9
This does not mean AI replaces the core disciplines that have always shaped peptide development. Computational methods can support exploration of sequence space, structure–activity relationships, target-binding hypotheses, and potential developability liabilities. For a modality in which small structural changes can alter potency, stability, solubility, permeability, and manufacturability, earlier prediction may help prioritize which candidates deserve deeper experimental investment.
The current peptide resurgence reflects that broader integration of enabling technologies. Recent peptide approvals and pipeline progress have been linked not only to advances in design and synthesis but also to display technologies, delivery systems, bioengineering, and AI.1 That combination matters because peptide development rarely turns on a single breakthrough. A computationally attractive sequence still must be synthesized, purified, characterized, formulated, delivered, and tested in biological systems. AI can help narrow the field, but it cannot eliminate the need to prove that a peptide behaves as expected in vitro, in vivo, and eventually in patients.
The most useful applications will likely be those that connect design prediction with pharmacology, chemistry, formulation, and manufacturability rather than treating target interaction as the only selection criterion. AI may expand the number and diversity of peptide candidates that can be considered, but successful peptide drugs still require experimental validation, chemistry expertise, delivery strategy, and manufacturing realism.
A Bridge to Manufacturing: Better Molecules Still Need Scalable Processes
The scientific resurgence of peptide drugs depends on more than improved discovery and design. A peptide candidate that performs well biologically must still be synthesized, purified, characterized, formulated, packaged, and supplied under quality expectations appropriate for clinical and commercial use. As more peptide programs move into larger indications, more complex molecular designs, and more competitive development timelines, manufacturing becomes part of the strategic equation rather than a downstream operational concern.
Solid-phase peptide synthesis (SPPS) has played an important role in making peptide production more practical and has helped expand the clinical-development pipeline.3 Its value lies in the ability to assemble peptide sequences through a controlled, stepwise process. Yet the same features that make SPPS powerful also create scale-up considerations. Longer sequences, structural modifications, protecting-group strategies, impurity control, solvent use, and purification burden can all influence whether a promising peptide can be manufactured efficiently and reproducibly.
Peptide production also involves more than synthesis alone. It includes purification, product isolation, raw-material procurement, primary packaging, quality control, and quality assurance. Each of those steps can affect cost, timeline, product quality, and supply reliability. A development program that does not account for those factors early may discover that a scientifically attractive molecule creates avoidable challenges later in the process.
That is why the peptide renaissance should be viewed as a full development ecosystem. Better molecules and better delivery strategies must be matched by manufacturing platforms, purification capacity, quality systems, and supply chain planning capable of supporting the intended product profile. The next phase of peptide growth will depend on how well the industry connects discovery promise with industrial execution.
The Next Phase of Peptide Precision Medicine
The renewed momentum behind peptide drugs reflects a practical evolution in therapeutic design. Peptides have always offered attractive biological properties, but their historical weaknesses limited how broadly they could be used. Today, stability, half-life, delivery route, permeability, exposure, and manufacturability are increasingly treated as design criteria from the earliest stages of development.
That shift helps explain why peptides fit the precision medicine era. Their structures can be tuned and adapted for specific targets and mechanisms, while advances in synthesis, delivery systems, bioengineering, and AI-enabled discovery are expanding the ways developers can improve their therapeutic potential. The success of GLP-1 drugs has made that progress highly visible, but the broader peptide opportunity extends across therapeutic, diagnostic, vaccine, and delivery applications.
The next phase of peptide innovation will depend on integration. Better molecular design must be connected to better delivery strategies. AI-enabled discovery must be grounded in experimental validation and developability. Structural modifications that improve pharmacology must remain compatible with scalable synthesis, purification, characterization, and quality control. As peptide candidates become more complex and as successful products reach larger patient populations, the boundaries between discovery, development, manufacturing, and supply will become harder to separate.
GLP-1 demand has shown that successful peptide medicines can place extraordinary pressure on manufacturing networks, from active pharmaceutical ingredient production to purification, fill-finish, packaging, devices, and distribution. For the field to keep advancing, the question will not simply be whether peptides can be designed to work. It will be whether they can be manufactured, supplied, and delivered reliably at the scale modern medicine now requires.
